Apalutamide Drug Asset Due Diligence Report 2026

This Apalutamide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

177

Registered trials

174

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Apalutamide can convert its Small molecule drug profile and AR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Apalutamide (query alias: apalutamide)
Modality / target	Small molecule drug; AR; AR antagonists
Highest global status	Approved
Originator	Janssen Global Services LLC
Active developers	Aragon Pharmaceuticals, Inc., Janssen Pharmaceutica NV, Janssen Research & Development LLC

The MCP disease footprint includes Metastatic Prostate Carcinoma, Metastatic castration-resistant prostate cancer, Hormone-dependent prostate cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600120362	Phase 2	Pending	29	Pathological Complete Response,pCR
NCT07428642	Not Applicable	Completed	168	Time to deep PSA response (PSA ≤ 0.2 ng/mL)
CTR20261207	Not Applicable	进行中（招募完成）	70	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial

Phase 2; n=48; evaluation: Positive. Reported fields: PSA(undetectable（≤ 0.2 ng/mL)) = 95.8 % ( 86.0 - 98.8)

Perioperative Apalutamide in High-Risk Localized Prostate Cancer

Phase 3; n=2109; evaluation: Positive. Reported fields: MFS(5-year) = 73.5 % ; MFS(5-year) = 78.2 %

Pharmacovigilance signals of androgen receptor pathway inhibitors in non-geriatric men with prostate cancer: A FAERS disproportionality analysis.

Not Applicable; n=1594913; evaluation: Positive. Reported fields: Asthenia = 4.79 ROR ; Asthenia = 1.69 ROR ; Asthenia = 2.11 ROR

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Apalutamide addresses Metastatic Prostate Carcinoma, Metastatic castration-resistant prostate cancer, Hormone-dependent prostate cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-10-17	科兴制药与苑东生物共拓阿帕他胺片海外市场	Approved	Financial terms not disclosed
2019-01-22	Nippon Shinyaku and J&J to co-promote Erleada in Japan	Approved	Financial terms not disclosed
	Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Inherited variants in SRD5a genes and response to hormonal therapy in prostate cancer”. The milestone feed surfaced a patent-application signal described as “Acyclic glutarimide compounds, compositions comprising same, and methods of use thereof”. The milestone feed surfaced a patent-application signal described as “Composition comprising crystalline nanosized apalutamide”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO